JPMorgan Chase & Co. raised its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 355.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 355,488 shares of the company's stock after purchasing an additional 277,355 shares during the quarter. JPMorgan Chase & Co. owned 0.29% of 10x Genomics worth $8,027,000 as of its most recent filing with the SEC.
A number of other large investors have also made changes to their positions in the stock. Arizona State Retirement System boosted its stake in 10x Genomics by 9.4% during the second quarter. Arizona State Retirement System now owns 26,617 shares of the company's stock worth $518,000 after buying an additional 2,287 shares in the last quarter. State of New Jersey Common Pension Fund D raised its position in 10x Genomics by 41.7% in the second quarter. State of New Jersey Common Pension Fund D now owns 84,118 shares of the company's stock worth $1,636,000 after purchasing an additional 24,761 shares in the last quarter. Federated Hermes Inc. bought a new position in 10x Genomics during the second quarter worth about $136,000. Renaissance Technologies LLC boosted its holdings in 10x Genomics by 301.1% during the second quarter. Renaissance Technologies LLC now owns 210,200 shares of the company's stock valued at $4,088,000 after purchasing an additional 157,800 shares in the last quarter. Finally, Primecap Management Co. CA boosted its holdings in 10x Genomics by 135.3% during the second quarter. Primecap Management Co. CA now owns 186,800 shares of the company's stock valued at $3,633,000 after purchasing an additional 107,400 shares in the last quarter. Institutional investors and hedge funds own 84.68% of the company's stock.
10x Genomics Price Performance
Shares of NASDAQ TXG traded down $0.46 during mid-day trading on Wednesday, hitting $14.98. The company's stock had a trading volume of 2,379,636 shares, compared to its average volume of 1,892,441. 10x Genomics, Inc. has a one year low of $12.95 and a one year high of $51.22. The company's fifty day simple moving average is $15.02 and its 200-day simple moving average is $18.02. The stock has a market cap of $1.81 billion, a price-to-earnings ratio of -9.79 and a beta of 1.83.
10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.34) by $0.04. The firm had revenue of $151.65 million for the quarter, compared to analysts' expectations of $158.84 million. 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. The business's revenue for the quarter was down 1.3% on a year-over-year basis. During the same period last year, the firm earned ($0.51) earnings per share. On average, sell-side analysts predict that 10x Genomics, Inc. will post -1.4 EPS for the current year.
Wall Street Analyst Weigh In
Several analysts recently commented on TXG shares. The Goldman Sachs Group decreased their price target on 10x Genomics from $16.00 to $14.00 and set a "sell" rating on the stock in a research note on Wednesday, October 30th. Stephens reaffirmed an "overweight" rating and issued a $30.00 target price on shares of 10x Genomics in a report on Thursday, October 10th. Barclays dropped their target price on shares of 10x Genomics from $21.00 to $19.00 and set an "overweight" rating for the company in a research report on Friday, November 1st. Canaccord Genuity Group reduced their price target on shares of 10x Genomics from $32.00 to $20.00 and set a "buy" rating on the stock in a research report on Thursday, October 10th. Finally, UBS Group cut their price objective on 10x Genomics from $25.00 to $20.00 and set a "neutral" rating for the company in a research report on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, 10x Genomics currently has a consensus rating of "Moderate Buy" and a consensus target price of $23.86.
Get Our Latest Stock Analysis on TXG
About 10x Genomics
(
Free Report)
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.
Read More
Before you consider 10x Genomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 10x Genomics wasn't on the list.
While 10x Genomics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
